Cargando…
Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells
PTEN is a tumor suppressor that is highly mutated in a variety of human cancers. Recent studies have suggested a link between PTEN loss and deficiency in the non-homologous end-joining (NHEJ) pathway of DNA double strand break (DSB) repair. As a means to achieve synthetic lethality in this context,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407680/ https://www.ncbi.nlm.nih.gov/pubmed/30863489 http://dx.doi.org/10.18632/oncotarget.26654 |
_version_ | 1783401609042067456 |
---|---|
author | Turchick, Audrey Liu, Yanfeng Zhao, Weixi Cohen, Inessa Glazer, Peter M. |
author_facet | Turchick, Audrey Liu, Yanfeng Zhao, Weixi Cohen, Inessa Glazer, Peter M. |
author_sort | Turchick, Audrey |
collection | PubMed |
description | PTEN is a tumor suppressor that is highly mutated in a variety of human cancers. Recent studies have suggested a link between PTEN loss and deficiency in the non-homologous end-joining (NHEJ) pathway of DNA double strand break (DSB) repair. As a means to achieve synthetic lethality in this context, we tested the effect of 3E10, a cell-penetrating autoantibody that inhibits RAD51, a key factor in the alternative pathway of DSB repair, homology dependent repair (HDR). We report here that treatment of PTEN-deficient glioma cells with 3E10 leads to an accumulation of DNA damage causing decreased proliferation and increased cell death compared to isogenic PTEN proficient controls. Similarly, 3E10 was synthetically lethal to a series of PTEN-deficient, patient-derived primary melanoma cell populations. Further, 3E10 was found to synergize with a small molecule inhibitor of the ataxia telangiectasia and Rad3-related (ATR) protein, a DNA damage checkpoint kinase, in both PTEN-deficient glioma cells and primary melanoma cells. These results point to a targeted synthetic lethal strategy to treat PTEN-deficient cancers through a combination designed to disrupt both DNA repair and DNA damage checkpoint signaling. |
format | Online Article Text |
id | pubmed-6407680 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-64076802019-03-12 Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells Turchick, Audrey Liu, Yanfeng Zhao, Weixi Cohen, Inessa Glazer, Peter M. Oncotarget Priority Research Paper PTEN is a tumor suppressor that is highly mutated in a variety of human cancers. Recent studies have suggested a link between PTEN loss and deficiency in the non-homologous end-joining (NHEJ) pathway of DNA double strand break (DSB) repair. As a means to achieve synthetic lethality in this context, we tested the effect of 3E10, a cell-penetrating autoantibody that inhibits RAD51, a key factor in the alternative pathway of DSB repair, homology dependent repair (HDR). We report here that treatment of PTEN-deficient glioma cells with 3E10 leads to an accumulation of DNA damage causing decreased proliferation and increased cell death compared to isogenic PTEN proficient controls. Similarly, 3E10 was synthetically lethal to a series of PTEN-deficient, patient-derived primary melanoma cell populations. Further, 3E10 was found to synergize with a small molecule inhibitor of the ataxia telangiectasia and Rad3-related (ATR) protein, a DNA damage checkpoint kinase, in both PTEN-deficient glioma cells and primary melanoma cells. These results point to a targeted synthetic lethal strategy to treat PTEN-deficient cancers through a combination designed to disrupt both DNA repair and DNA damage checkpoint signaling. Impact Journals LLC 2019-02-12 /pmc/articles/PMC6407680/ /pubmed/30863489 http://dx.doi.org/10.18632/oncotarget.26654 Text en Copyright: © 2019 Turchick et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Priority Research Paper Turchick, Audrey Liu, Yanfeng Zhao, Weixi Cohen, Inessa Glazer, Peter M. Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells |
title | Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells |
title_full | Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells |
title_fullStr | Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells |
title_full_unstemmed | Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells |
title_short | Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells |
title_sort | synthetic lethality of a cell-penetrating anti-rad51 antibody in pten-deficient melanoma and glioma cells |
topic | Priority Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407680/ https://www.ncbi.nlm.nih.gov/pubmed/30863489 http://dx.doi.org/10.18632/oncotarget.26654 |
work_keys_str_mv | AT turchickaudrey syntheticlethalityofacellpenetratingantirad51antibodyinptendeficientmelanomaandgliomacells AT liuyanfeng syntheticlethalityofacellpenetratingantirad51antibodyinptendeficientmelanomaandgliomacells AT zhaoweixi syntheticlethalityofacellpenetratingantirad51antibodyinptendeficientmelanomaandgliomacells AT coheninessa syntheticlethalityofacellpenetratingantirad51antibodyinptendeficientmelanomaandgliomacells AT glazerpeterm syntheticlethalityofacellpenetratingantirad51antibodyinptendeficientmelanomaandgliomacells |